title: Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients.
abstract: In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.
authors.affiliation: Department of Internal Medicine, Section on Infectiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: Casper
authors.initials: C
authors.lastname: Rokx
authors.forename: Marchina E
authors.initials: ME
authors.lastname: van der Ende
authors.forename: Annelies
authors.initials: A
authors.lastname: Verbon
authors.forename: Bart J A
authors.initials: BJ
authors.lastname: Rijnders
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
keywords: HIV/AIDS; Kaposi sarcoma; highly active antiretroviral therapy; peginterferon alfa-2a; treatment effectiveness